Continuing Education
Novo Nordisk Inc. supports accredited continuing education (CE) for healthcare professionals across therapeutic areas of interest. These CE activities are planned, developed and delivered by independent accredited providers in accordance with the standards set forth in the ACCME Standards for Integrity and Independence in Accredited Continuing Education, or the standards of other similar accrediting organizations. Novo Nordisk Inc. does not exercise control over, or provide guidance to, any accredited provider. Novo Nordisk Inc. is sharing CE information on this page as a service to the medical community and with permission from the accredited providers. The information on this page is intended to provide self-service to educational topics of interest and most activities are free to the learner (some may require a nominal registration fee per the accredited provider’s requirements).
Click below to filter results by Therapeutic Area.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Diabetes
A Holistic Approach: Tailoring T2D Therapy With GLP-1 RAs
Expiration Date: June 28, 2025
Expert Insights on Managing T2D With GLP-1 RAs
Expiration Date: June 28, 2025
Addressing Underutilization of Cardioprotective GLP-1 RAs for T2D in Specialty Practice
Expiration Date: July 31, 2025
Expiration Date: August 6, 2025
Expiration Date: September 26, 2025
Patient POV: Shared Decision Making in the Management of T2DM with Comorbidities
Expiration Date: September 29, 2025
Expiration Date: October 23, 2025
The New Normal: Digital Technologies for People Living With Insulin-Treated Type 2 Diabetes
Expiration Date: October 31, 2025
What Primary Care Clinicians Need to Know About Once-Weekly Insulins
Expiration Date: October 31, 2025
Expiration Date: November 22, 2025
GLP-1 Receptor Agonists in Type 2 Diabetes: Updates and Insights for Pharmacists
Expiration Date: November 22, 2025
Expiration Date: December 6, 2025
Utilizing GLP-1 Receptor Agonists for Type 2 Diabetes: Listening to What Patients Have to Say
Expiration Date: December 13, 2025
The Latest in Stroke Risk Reduction Strategies: Are Your Patients Protected?
Expiration Date: January 02, 2026
Chronic Kidney Disease and GLP-1 Ras
Expiration Date: September 10, 2026
GLP-1 RAs: Selecting the Right Patient at the Right Time
Expiration Date: April 14, 2027
Initiating Basal Insulin: Moving from Hesitancy to Action
Expiration Date: April 21, 2026
Type 2 Diabetes Medications: The intersection of new science and guidelines
Expiration Date: May 14th, 2026
Expiration Date: May 25, 2027
Putting Evidence into Practice: Tips for Starting and Continuing GLP-1 RAs
Expiration Date: June 13, 2027
A Community Pharmacy’s Guide to the Evolving Role of GLP-1 Receptor Agonists for Diabetes
Expiration Date: August 22, 2027
Obesity
Managing Obesity & Cardiovascular Risk with GLP-1 RAs
Expiration Date: June 28, 2025
Management of Complications of Obesity
Expiration Date: June 20, 2025
Managing Obesity in Adolescent Patients: Your Top 10 Questions Answered
Expiration Date: August 15, 2025
Shifting Perspectives in Obesity Management: A Call to Action for Cardiologists
Expiration Date: August 29, 2025
Expiration Date: September 30, 2025
Weight Matters – Managing CV Risk with Evidence-Based Strategies
Expiration Date: November 1, 2025
Practical Strategies for Obesity Management in Primary Care
Expiration Date: December 31, 2025
Expiration Date: December 31, 2025
Overcoming Bias and Engaging in Meaningful Conversations Regarding Obesity Management
Expiration Date: December 31, 2025
Expiration Date: December 31, 2025
Managing Obesity and Cardiovascular Comorbidities in Primary Care
Expiration Date: February 16, 2026
Modifying Obesity Treatment Based on Weight Loss Goals, Comorbidities, and Adverse Event Management
Expiration Date: February 20, 2026
Recognizing Obesity as a Chronic Disease
Expiration Date: March 5, 2026
Expiration Date: March 5, 2026
A Weight Loss Journey in Primary Care: Integrating Obesity Medication Into Treatment Plans
Expiration Date: March 12, 2026
Discussing Obesity and Obesity Medication with Patients
Expiration Date: March 19, 2026
Optimizing Pharmacologic Options for Obesity Management
Expiration Date: April 2, 2026
In the Hot Seat: Experts Weigh in on Weight Management
Expiration Date: April 30, 2026
Managing Adolescents with Obesity
Expiration Date: April 30, 2026
Treating Concomitant Obesity and Type 2 Diabetes
Expiration Date: May 14, 2026
Mechanisms, Pathophysiology, and Management of Obesity
Expiration Date: March 21, 2027
Pharmacological and Surgical Management of Obesity
Expiration Date: June 25, 2027
Obesity Management Considerations in Diverse Populations
Expiration Date: August 27, 2027
Expiration Date: January 10, 2027
Changing the Conversation on Obesity
Expiration Date: February 1, 2027
Screening, Diagnosis, and Assessment of Individuals with Obesity
Expiration Date: February 28, 2027
Cardiovascular Disease
Expert Insights on Targeting Residual Inflammatory Risk in ASCVD and CKD
Expiration Date: July 21, 2025
Expiration Date: August 22, 2025
Management of ASCVD in Patients with CKD: Present, Past, and Future (Module 2)
Expiration Date: August 28, 2025
Exploring the Link Between Systemic Inflammation, Atherosclerosis, and CKD (Module 1)
Expiration Date: August 30, 2025
Inflammation Unveiled – Tackling Residual Risk in ASCVD and CKD
Expiration Date: September 4, 2025
Inflammation Unveiled – Tackling Residual Risk in ASCVD and CKD
Expiration Date: September 4, 2025
Reducing ASCVD risk in people living with CKD: the emerging role of systemic inflammation
Expiration Date: September 30, 2025
Expiration Date: October 15, 2025
Kidney Commute Podcast: Reducing ASCVD Risk in CKD
Expiration Date: October 30, 2026
Inflammation, ASCVD, and CKD – Addressing Residual Risk
Expiration Date: November 1, 2025
Navigating the Intersection of Cardiorenal Disease: A Multidisciplinary Approach
Expiration Date: January 13, 2026
Importance of Timely Interventions: Current Management of CV Risk in People With CKD
Expiration Date: January 13, 2026
Looking to the Future: Directly Targeting Inflammation with Emerging Therapies
Expiration Date: January 13, 2026
Chronic Kidney Disease
We are still gathering material for this section. Please check again soon.
Liver Health
Endocrinologists and PCPs: The Frontline Defense Against Cirrhosis in Patients with Type 2 Diabetes
Expiration Date: June 13, 2025
Redefining MASLD/MASH Care: Personalized Strategies for Assessment, Diagnosis, and Management
Expiration Date: June 12, 2025
Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?
Expiration Date: June 19, 2025
Ace The Case #2 - A 60-Year-Old Type 2 Diabetic Woman with Mash and F3 Liver Fibrosis
Expiration Date: June 19, 2025
Ace The Case #1 – A 37-Year-Old Man with Incidental Hepatic Steatosis on Abdominal Ultrasound
Expiration Date: June 19, 2025
Expiration Date: July 2, 2025
Expiration Date: July 3, 2025
Expert Perspectives – Post Conference Highlights on MASLD/MASH
Expiration Date: July 11, 2025
Patient-Centric Care: Tailoring MASLD Management for Optimal Outcomes
Expiration Date: September 30, 2025
New insights on the role of GLP-1 in the treatment of MASH
Expiration Date: October 25, 2025
MASH Academy: Advanced Care Strategies for Metabolic Dysfunction-Associated Steatohepatitis
Expiration Date: October 25, 2025
MASH Academy: Non-invasive monitoring techniques for patients with MASH
Expiration Date: November 1, 2025
What’s New in MASH: Strengthening Your Diagnostic and Management Muscles
Expiration Date: November 1, 2025
Expert Perspectives Post Conference Highlights on MASLD/MASH from ACG
Expiration Date: November 7, 2025
Post Conference Highlights from AASLD
Expiration Date: November 27, 2025
Mastering Management of MASLD and MASH: Evidence-based Approaches for Endocrinology HCPs
Expiration Date: December 1, 2025
A Patient with Cardiometabolic Conditions That Place Them at High Risk for MASLD
Expiration Date: December 6, 2025
A Patient with Abnormal Liver Enzymes
Expiration Date: December 6, 2025
Expiration Date: December 17, 2025
Expiration Date: December 28, 2025
Expert Perspectives: Post Conference Highlights on MASLD/MASH
Expiration Date: December 31, 2025
Hot Topics in Chronic Liver Disease and GI Disorders
Expiration Date: December 31, 2025
Expiration Date: February 10, 2026
MASH Matters: Multidisciplinary Strategies for Translating the Latest Evidence Into Practice
Expiration Date: February 10, 2026
Addressing the Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know
Expiration Date: April 3, 2026
Can You Master MASH Diagnosis & Management?
Expiration Date: June 3, 2026
Neuro Health
Expiration Date: December 23, 2025
Expiration Date: March 9, 2026
Rare Bleeding Disorders
Integrating Novel Therapies in Hemophilia in the Midst of Bridging Health Inequities
Expiration Date: May 14, 2025
Latest Developments in the Treatment of Hemophilia: Focus on Anti-Tissue Factor Pathway Inhibitors
Expiration Date: June 4, 2025
Does Labeling the Level of Severity in Hemophilia Block Access to Optimized Care?
Expiration Date: July 12, 2025
Improving the Patient Experience: Emerging Therapies (Episode 3)
Expiration Date: July 22, 2025
Improving the Patient Experience: New Therapies (Episode 2)
Expiration Date: July 22, 2025
The Burden of Living with Hemophilia (Episode 1)
Expiration Date: July 22, 2025
Racial and Ethnic Disparities in the Context of New and Emerging Treatments for Hemophilia
Expiration Date: July 22, 2025
Exploring Non-Factor Replacement Therapies for Hemophilia Care: Achieving Positive Outcomes
Expiration Date: August 22, 2025
Innovations in Hemophilia Treatment: Current and Emerging Non-Factor Therapies
Expiration Date: September 20, 2025
Overcoming the Hurdles: Advances in the Management of Hemophilia
Expiration Date: September 27, 2025
Optimizing Patient Outcomes in Hemophilia: Integrating Non-Factor Approaches and Addressing Barriers
Expiration Date: October 8, 2025
Clinical Consults: Providing Comprehensive Hemophilia Care in the Era of Non-Factor Therapies
Expiration Date: October 9, 2025
Expiration Date: January 31, 2026
Expiration Date: January 31, 2026
Expiration Date: January 31, 2026
Rebalancing Therapies for Hemophilia: Are You Ready?
Expiration Date: February 26, 2026
Rare Endocrine Disorders
Evolving Treatment Paradigms for Growth Hormone Deficiency: Integrating Novel Therapies
Expiration Date: September 20, 2025
GHD: Transitioning Patients from Daily GH to LAGH Preparations
Expiration Date: November 30, 2025
GHD: Individualized IGF-I Monitoring Strategies for GH and LAGH Therapy
Expiration Date: November 30, 2025
GHD 2025: Diagnosis, Management & Evolving Therapies
Expiration Date: November 30, 2025
Rare Renal Disorders
Hemoglobinopathies
Expiration Date: November 24, 2025
Bridging Gaps and Advancing Care in Sickle Cell Disease in the Context of Drug Therapy
Expiration Date: December 20, 2025
Thinking Beyond Pain Crisis Management in Patients with Sickle Cell Disease
Expiration Date: December 7, 2025
Key Advances in Rare Blood Diseases in 2024: A Year in Review
Expiration Date: January 29, 2026
Expiration Date: March 12, 2026
Managing Uncomplicated Sickle Cell Crisis: Best Practices for Optimal Outcomes
Expiration Date: September 1, 2028
Find more information
Speak to a medical representative
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
